Key findings include: Mean weight loss of 24.2% (approximately 58 pounds or 26.2 kg) with 12 mg weekly dose after 48 weeks Dose-dependent efficacy across 1 mg, 4 mg, 8 mg, and 12 mg dose groups At 48 weeks, 100% of participants receiving 8 mg or 12 mg achieved at least 5% weight loss 93% of participants on 12 mg achieved 15% or more weight loss , far exceeding current therapeutic benchmarks Greater weight reduction observed in participants with BMI greater than or equal to 35 compared to those with BMI below 35 The magnitude of weight loss approaches that typically observed only with bariatric-metabolic surgery, representing a potential paradigm shift in pharmacological obesity treatment[11]
BOOST announced a new protein shake designed for people using GLP-1 medications for weight loss
El Lillys (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage
However, even with biochemically optimized thyroid function, many patients continue to experience difficulty with weight management
Offered as a daily tablet, oral semaglutide provides a convenient alternative for those preferring a needle-free treatment
Professor Elzbieta Lorenc-Koci for her suggestion to use this neurodevelopmental model of schizophrenia in research